OmniComm Systems, Inc. Responds to Industry's Growing Demand for Integrated Electronic Data Capture (EDC) Solutions and Signs 15 New Deals in Second Quarter 2007
FT. LAUDERDALE, FL, July 23, 2007-/MarketWire/-OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that they have closed 15 new business deals in Q2, 2007. Key market segments for the new business include pharmaceutical, medical device, contract research organizations (CRO) and academic medical center customers, including a high profile Top 50 pharmaceutical company. TrialMaster will be implemented in both an ASP, fully hosted environment for the new trials and also in 2 new Technology Transfer deployments for those clients that want to bring EDC in-house.
OmniComm’s Sr. Vice President of Business Development, Stephen Johnson, commented, “The company’s escalating growth is a direct result of the drug development industry’s need for flexible and integrated solutions for clinical trials. TrialMaster provides sponsors with a feature rich EDC product that is easy to use, easy to integrate with and is not laden with hidden or exorbitant costs.” Added Johnson, “Our Support and Consulting Services groups are made up of industry veterans that stand ready to deliver quality driven solutions and support for our customers using EDC.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.